☆ 4.6 Meeting Abstract

Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis

JOURNAL OF THORACIC ONCOLOGY (2018)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 13, Issue 10, Pages S339-S339

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2018.08.277

Keywords

pembrolizumab; Mesothelioma; PD-L1

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.